|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||14.55 - 14.85|
|52 Week Range||11.90 - 20.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.67|
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance. Sometimes it becomes difficult to measure the efficiency level of a company. Inventory Turnover: The ratio of 12-month cost of goods sold (COGS) to a four-quarter average inventory is considered one of the most popular efficiency ratios.
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with its price performance.
Conference Call and Webcast to Follow WASHINGTON , April 18, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2018 ...
U.S. Court of Appeals Affirms District Court's Decision WASHINGTON , April 13, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for ...
WASHINGTON , April 9, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced participation at the 2018 Georg Rajka International Symposium of Atopic Dermatitis (ISAD 2018) ...
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Vanda Pharmaceuticals Inc (NASDAQ:VNDA) as an investment opportunity. Anyone interestedRead More...
WASHINGTON, March 15, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA) today announced the sale of 5,500,000 shares of its common stock in an underwritten public offering at a price to the public of $17.00 per share. The gross offering proceeds to Vanda from the sale of the shares are expected to be approximately $93.5 million. After deducting underwriting discounts and commissions and other estimated offering expenses, the net offering proceeds to Vanda are expected to be approximately $87.6 million.
WASHINGTON, March 14, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Vanda also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering are to be sold by Vanda, with net proceeds to be used for commercial and research and development activities and other general corporate purposes.
WASHINGTON , March 6, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in March 2018 . The ...
Vanda officials said they were able to show Hetlioz, their drug approved in the U.S. and Europe for a circadian rhythm condition known as non-24 sleep-wake disorder, showed "meaningful benefits" in addressing the symptoms of jet lag disorder . "Hetlioz improved both nighttime sleep and daytime alertness, potentially offering benefits to millions of travelers," said Dr. Mihael Polymeropoulos, CEO of Vanda, in a conference call with analysts on Monday. The trial results didn't move Vanda's stock very much Monday afternoon — it gained 30 cents, or 1.6 percent, to close at $19.30 per share on average trading volume — but that may be because of the additional challenges facing the company to get federal approval and market penetration for a jet lag disorder drug.
- HETLIOZ® demonstrates improvement in Total Sleep Time by 85 minutes versus Placebo (p - HETLIOZ® demonstrates improvement in Next Day Alertness versus Placebo (p Management to host conference call today ...
Headquartered in Dublin, Ireland, Alkermes (ALKS) is an integrated biopharmaceutical company engaged in the research, development, and commercialization of pharmaceutical products. Of the 12 analysts covering Alkermes (ALKS) in February 2018, five analysts gave the stock a “buy” or a higher rating.
Stock Monitor: Vanda Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 26, 2018 / Active-Investors.com has just released a free research report on Kadmon Holdings, Inc. (NYSE: KDMN ). If ...
What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Investors can expect a slew of critical developments from Vanda Pharmaceuticals (VNDA) in 2018. It expects to begin a tradipitant Phase 3 study in the first half of 2018 for atopic dermatitis and publish results from the tradipitant clinical study for the treatment of gastroparesis by the end of fiscal 2018.
The increase was due to an expansion of the Fanapt sales force and marketing efforts by Vanda Pharmaceuticals for Fanapt and Hetlioz. Total operating expenses incurred by Vanda Pharmaceuticals were $181.9 million in fiscal 2017 compared with $164.5 million in fiscal 2016. In the next part of this series, we’ll look at the key events to watch in Vanda Pharmaceuticals’ product pipeline.
What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Vanda Pharmaceuticals (VNDA) is a biopharmaceutical company with a focus on developing and commercializing innovative therapies. Vanda Pharmaceuticals has adopted a five-pronged business strategy with a goal of becoming a leading global biopharmaceutical company.
Full year 2017 total revenues grew to $165.1 million , a 13% increase compared to 2016 WASHINGTON , Feb. 14, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial ...
NEW YORK, NY / ACCESSWIRE / February 14, 2018 / Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 14, 2018 at 4:30 PM ...
NEW YORK, Feb. 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Omega ...
Conference Call and Webcast to Follow WASHINGTON , Jan. 30, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter and full ...
WASHINGTON, Jan. 7, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA), a biopharmaceutical company focused on the development and commercialization of novel therapies addressing high unmet medical needs, today announced preliminary unaudited financial results for the fourth quarter and full year 2017 and its financial guidance for 2018. Vanda expects to report 2017 total net product sales from HETLIOZ® and Fanapt® of approximately $165 million, consistent with Vanda's prior guidance of between $163 million and $169 million. HETLIOZ® net product sales for 2017 are expected to be approximately $90 million, consistent with Vanda's prior guidance of between $89 million and $92 million.